RE: anticipating the results of the staregic reviYour way off base Palnic.
The new CEO stated when he came on board that he was going to do a due diligence on all the drugs and after the strategic review, he would share with investors and analysts his strategy going forward.
His comments could dramatically change the view on the stock. He also said that he would not rule out acquisitions as part of a growth strategy.
So he may decide to license some of the new drugs or run them on their own. This CEO has been very successful in the past, so I believe that analysts are very interested in the course he wants to take with the company.
I don't think that anyone is expecting partnership news out of this review. He has only been aboard for 4-5 months and he has not had time to fully understand the process let alone pitch to another company.
I hope you do not own this stock. You should have a better understanding of what you own.
The value of this company lies in 2008 Phase 3 results of the BPH drugs.